about
Follow-up of potential novel Graves' disease susceptibility loci, identified in the UK WTCCC genome-wide nonsynonymous SNP studyGenome-wide association analysis of autoantibody positivity in type 1 diabetes cases.Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts.Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves' disease.Use of Tag single nucleotide polymorphisms (SNPs) to screen PTPN21: no association with Graves' disease.Endothelial nitric oxide synthase single nucleotide polymorphism and left ventricular function in early chronic kidney disease.Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond.The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin deficiencyThe search for the genetic contribution to autoimmune thyroid disease: the never ending story?GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis.Using Genetic Variation to Predict and Extend Long-term Kidney Transplant Function.Genetic predictors of long-term graft function in kidney and pancreas transplant patients.Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease.Impact of month of birth on the development of autoimmune thyroid disease in the United Kingdom and Europe.Confirmation of association of chromosome 5q31-33 with United Kingdom Caucasian Graves' disease.Evaluation of five interleukin genes for association with end-stage renal disease in white Europeans.A systematic approach to the assessment of known TNF-alpha polymorphisms in Graves' disease.Skewed X chromosome inactivation and female preponderance in autoimmune thyroid disease: an association study and meta-analysis.Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease.Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves' ophthalmopathy.A single nucleotide polymorphism in the CD40 gene on chromosome 20q (GD-2) provides no evidence for susceptibility to Graves' disease in UK Caucasians.Association of Caveolin-1 Gene Polymorphism With Kidney Transplant Fibrosis and Allograft FailureA nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves' disease: Comment on the article by Rood et alAssociation of the BTNL2 rs2076530 single nucleotide polymorphism with Graves' disease appears to be secondary to DRB1 exon 2 position beta74A novel and major association of HLA-C in Graves' disease that eclipses the classical HLA-DRB1 effectThe CD40 Kozak SNP: a new susceptibility loci for Graves' disease?Analysis of HLA class II genes in Hashimoto's thyroiditis reveals differences compared to Graves' diseaseIL-13 and chromosome 5q31-q33: problems of identifying association within regions of linkage to Graves' diseaseAssociation of FcGRIIa with Graves' disease: a potential role for dysregulated autoantibody clearance in disease onset/progressionGenetic variation in caveolin-1 correlates with long-term pancreas transplant functionUsing PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation
P50
Q24597671-CA8C5667-E753-4EF1-9F07-4A842AA561E6Q29417005-0B60D9D0-AC64-4B06-9F86-3F53818940ABQ30992731-3164891B-ADB8-4CE1-97E6-8143DDF2266DQ34480522-36F7FDB8-F16F-4049-AFD1-F97DD38893D5Q34558663-5B8AB4DA-556E-44B6-9E21-6BF1EB2ABB2AQ35001614-CB41760F-FB0F-42AA-AC13-9A7AB8CC0C84Q35696684-102E0767-F79A-4ADD-BB84-303DAD88090DQ36782392-C5B31CBB-602C-4672-802E-D65A7E32F1BCQ37857568-AB167E14-25F3-4FF4-B0A2-CC967D9734D4Q38093041-5F718F55-7B1A-49FC-8DF0-2E4AEADB7568Q38564366-E875818D-AC95-4CAC-9CD5-9703B682705CQ38767421-7253BAC0-AA98-41BF-AA3F-375310D97DDBQ40471430-3A3CEC06-F950-46DB-ADC6-997F328DA11BQ42217886-00231981-B08C-47FB-B3B7-2DBF0D5940DEQ43530520-D5D382D6-3C90-4F73-99C4-EF3BAD067C10Q45195190-9117BC0F-3ADE-4AE8-9DED-863DC1B45366Q47840935-651E087C-A403-42DD-B98A-6F4C22912215Q51188078-F8698AA4-0720-4271-B666-BB51386A0C31Q51798434-03838BE9-C189-4187-8ADE-169AFEC30813Q53543182-E66B1C29-F0B3-4018-90FD-331FF7CC6520Q54708794-B211B116-5119-4B41-8B6D-2DE8468C72AFQ60544423-80C2635B-7AEF-4F9F-8E88-B74242BD0515Q78505571-A4B5A48A-7C7A-488B-B9D9-A22020708A4BQ80290203-AC3BC0C0-139E-4A30-A0EE-6E1880E46095Q80539372-3E83A7E5-D6AF-406D-8A50-D124F8BED3F5Q80975128-6339D12B-A68E-42CB-A44E-C90863E16C04Q81193861-65ACF550-D882-4F8A-BB0E-C4782A8C5F5BQ81604829-B60D9CB1-7285-4651-925D-F1A1E1726E75Q82866159-A42A6ADB-A2BF-4808-8B7C-29D74216B1B5Q86954735-A4C45EFA-D426-4840-B86B-9DF0A3FFF44FQ91352305-1E27F153-4E27-409E-979F-1BDB09A79698
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Matt Simmonds
@ast
Matt Simmonds
@en
Matt Simmonds
@es
Matt Simmonds
@nl
type
label
Matt Simmonds
@ast
Matt Simmonds
@en
Matt Simmonds
@es
Matt Simmonds
@nl
prefLabel
Matt Simmonds
@ast
Matt Simmonds
@en
Matt Simmonds
@es
Matt Simmonds
@nl
P108
P106
P1153
9846749100
P31
P496
0000-0003-3154-3510